Danial E Baker

Summary

Affiliation: Washington State University
Country: USA

Publications

  1. ncbi request reprint Certolizumab pegol for the treatment of Crohn's disease
    Danial E Baker
    Director, Drug Information Center Professor of Pharmacotherapy, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, WA 99210 1495, USA
    Expert Rev Clin Immunol 5:683-91. 2009
  2. ncbi request reprint Rationale for using serotonergic agents to treat irritable bowel syndrome
    Danial E Baker
    College of Pharmacy, Washington State University, P O Box 1495, Spokane, WA 99210 1495, USA
    Am J Health Syst Pharm 62:700-11; quiz 712-3. 2005
  3. ncbi request reprint Inhaled dry powder insulin for the treatment of diabetes mellitus
    Stephen M Setter
    Department of Pharmacotherapy, College o f Pharmacy, Washington State University, Spokane, WA 99217 6131, USA
    Clin Ther 29:795-813. 2007
  4. ncbi request reprint Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus
    Jason L Iltz
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, 99210 1495, USA
    Clin Ther 28:652-65. 2006
  5. ncbi request reprint Insulin glargine: a new basal insulin
    Terri L Levien
    College of Pharmacy, Washington State University Spokane, 99202 1675, USA
    Ann Pharmacother 36:1019-27. 2002
  6. ncbi request reprint The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, WA, USA
    Rev Gastroenterol Disord 4:86-91. 2004
  7. ncbi request reprint Phosphodiesterase 5 inhibitors for erectile dysfunction
    Stephen M Setter
    Department of Pharmacotherapy, College of Pharmacy, Washington State University Elder Services, Spokane, WA 99217 6131, USA
    Ann Pharmacother 39:1286-95. 2005
  8. ncbi request reprint Natalizumab: overview of its pharmacology and safety
    Danial E Baker
    College of Pharmacy, Washington State University Spokane, Spokane, Washington, USA
    Rev Gastroenterol Disord 7:38-46. 2007
  9. ncbi request reprint Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, Washington, USA
    Rev Gastroenterol Disord 3:150-7. 2003
  10. ncbi request reprint Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole
    Danial E Baker
    Drug Information Center, Department of Pharmacotherapy, Washington State University, Spokane, USA
    Rev Gastroenterol Disord 9:E111-8. 2009

Detail Information

Publications18

  1. ncbi request reprint Certolizumab pegol for the treatment of Crohn's disease
    Danial E Baker
    Director, Drug Information Center Professor of Pharmacotherapy, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, WA 99210 1495, USA
    Expert Rev Clin Immunol 5:683-91. 2009
    ..Concomitant use with anakinra is not recommended because of the increased risk of serious infections and neutropenia. Therapy should be discontinued if the patient develops a serious infection during therapy...
  2. ncbi request reprint Rationale for using serotonergic agents to treat irritable bowel syndrome
    Danial E Baker
    College of Pharmacy, Washington State University, P O Box 1495, Spokane, WA 99210 1495, USA
    Am J Health Syst Pharm 62:700-11; quiz 712-3. 2005
    ....
  3. ncbi request reprint Inhaled dry powder insulin for the treatment of diabetes mellitus
    Stephen M Setter
    Department of Pharmacotherapy, College o f Pharmacy, Washington State University, Spokane, WA 99217 6131, USA
    Clin Ther 29:795-813. 2007
    ..Inhaled dry powder insulin (IDPI) is the first inhaled insulin approved for the treatment of type 1 and type 2 diabetes mellitus (DM)...
  4. ncbi request reprint Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus
    Jason L Iltz
    Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, 99210 1495, USA
    Clin Ther 28:652-65. 2006
    ....
  5. ncbi request reprint Insulin glargine: a new basal insulin
    Terri L Levien
    College of Pharmacy, Washington State University Spokane, 99202 1675, USA
    Ann Pharmacother 36:1019-27. 2002
    ..To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine...
  6. ncbi request reprint The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, WA, USA
    Rev Gastroenterol Disord 4:86-91. 2004
    ..If patients are unable to tolerate any one of these three 5-aminosalicylic acid-releasing preparations, they might be able to tolerate one of the others, as long as the intolerance is not due to hypersensitivity to 5-aminosalicylic acid...
  7. ncbi request reprint Phosphodiesterase 5 inhibitors for erectile dysfunction
    Stephen M Setter
    Department of Pharmacotherapy, College of Pharmacy, Washington State University Elder Services, Spokane, WA 99217 6131, USA
    Ann Pharmacother 39:1286-95. 2005
    ..To review the pharmacologic and clinical trial data of the Food and Drug Administration-approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED)...
  8. ncbi request reprint Natalizumab: overview of its pharmacology and safety
    Danial E Baker
    College of Pharmacy, Washington State University Spokane, Spokane, Washington, USA
    Rev Gastroenterol Disord 7:38-46. 2007
    ..This program requires all patients prescribed natalizumab to be enrolled in and to receive their medication through the TOUCH system. Any serious adverse reactions must be reported to the TOUCH and MedWatch systems...
  9. ncbi request reprint Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, Washington, USA
    Rev Gastroenterol Disord 3:150-7. 2003
    ..However, measuring the TPMT activity at baseline is not a substitute for monitoring white blood cell counts throughout therapy because drug therapy and/or other conditions may still cause myelosuppression in these patients...
  10. ncbi request reprint Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole
    Danial E Baker
    Drug Information Center, Department of Pharmacotherapy, Washington State University, Spokane, USA
    Rev Gastroenterol Disord 9:E111-8. 2009
    ..What remains to be seen is whether oral therapy can be substituted for all, or part, of the 72-hour IV infusion and whether the patient can be discharged from the hospital sooner with similar outcomes...
  11. ncbi request reprint Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction
    Danial E Baker
    Drug Information Center, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA, USA
    Rev Gastroenterol Disord 9:E84-93. 2009
    ..Methylnaltrexone appears effective in the therapy of opioid-induced constipation and will be useful for patients failing to respond to traditional laxative regimens...
  12. ncbi request reprint Imatinib mesylate
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, WA, USA
    Rev Gastroenterol Disord 2:75-86. 2002
    ....
  13. ncbi request reprint Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, WA, USA
    Rev Gastroenterol Disord 2:20-33. 2002
    ..g., avoid lying down for 30 minutes after taking the drug and take the drug with a full glass of water) and may be decreased with once-weekly dosing...
  14. ncbi request reprint Intravenous proton pump inhibitors
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, Washington, USA
    Rev Gastroenterol Disord 6:22-34. 2006
    ....
  15. ncbi request reprint Safety of balsalazide therapy in the treatment of inflammatory bowel disease
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, Washington, USA
    Rev Gastroenterol Disord 5:135-41. 2005
    ..Overall, balsalazide is well tolerated and effective in the treatment of IBD...
  16. ncbi request reprint Esomeprazole: update and clinical review
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, Washington, USA
    Rev Gastroenterol Disord 2:189-99. 2002
    ..The results of these studies indicate that all the proton pump inhibitors are effective in treating GERD and erosive esophagitis and that some patients would benefit from esomeprazole therapy...
  17. ncbi request reprint Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, WA, USA
    Rev Gastroenterol Disord 3:93-109. 2003
    ..Studies directly comparing peginterferon alfa-2a and peginterferon alfa-2b have not been performed...
  18. ncbi request reprint Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B
    Danial E Baker
    College of Pharmacy, Washington State University, Spokane, Washington, USA
    Rev Gastroenterol Disord 5:89-100. 2005
    ..Lactic acidosis and severe hepatomegaly with steatosis may also occur during therapy...